Mette M. Ilander

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

TIM3 blockade with hypomethylating therapy restores NK-cell and cytotoxic CD4+ T-cell activity in patients with AML or MDS.

TIM3 blockade with hypomethylating therapy restores NK-cell and cytotoxic CD4+ T-cell activity in patients with AML or MDS.

Journal: Cancer immunology research
Published: February 04, 2026

Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.

Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.

Journal: Leukemia
Published: March 31, 2023

Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma.

Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma.

Journal: The Journal of clinical investigation
Published: August 25, 2022

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

Journal: Annals of hematology
Published: June 20, 2022

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma.

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma.

Journal: Oncoimmunology
Published: January 10, 2022

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.

Journal: The Journal of clinical investigation
Published: July 06, 2021

β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection.

β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection.

Journal: Cancer immunology research
Published: February 08, 2021

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.

Journal: Cancer immunology, immunotherapy : CII
Published: August 20, 2019

Novel TMEM173 Mutation and the Role of Disease Modifying Alleles.

Novel TMEM173 Mutation and the Role of Disease Modifying Alleles.

Journal: Frontiers in immunology
Published: August 07, 2019

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival.

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival.

Journal: Blood advances
Published: August 02, 2019

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.

Journal: Leukemia research
Published: March 20, 2019

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.

Journal: Nature communications
Published: February 22, 2019
Showing 1-12 of 27

Last Updated: 09/26/2026